Objectives To evaluate the usefulness of real-time polymerase chain reaction (RT-PCR) as a diagnostic method for the detection of Bordetella pertussis in hospitalized patients aged <1 year with a clinical diagnosis of whooping cough, as well as to identify the role of household contacts as a source of infection.
including the National Institute of Pediatrics (INP) and 4 other centers located in Mexico City and 6 centers distributed throughout Mexico (Appendix; available at www.jpeds.com). The INP served as the reference center for the microbiological studies. Table I (available at www.jpeds.com) summarizes the patients admitted in each hospital.
All infants aged <1 year who were hospitalized with any clinical symptoms suspicious of pertussis (eg, cough, paroxysmal cough, cyanosis, posttussive emesis, inspiratory "whoop," apnea), were included. Patients were included regardless of the duration of symptoms. The patients were evaluated by caregiver interview and physical examination. Documented data included the hospital of origin, age, sex, presence of fever, clinical symptoms suspicious of pertussis as mentioned above, conjunctival hemorrhage, as well as the presence of such complications as encephalopathy, seizures, heart failure, hypoglycemia, pneumonia, the need for mechanical ventilation, pediatric intensive care unit (PICU) admission, and related deaths. In addition, complete cell count was performed and when necessary, chest radiography was performed.
Respiratory samples were obtained using nylon nasopharyngeal swabs (FLOQ Swabs; COPAN, Murrieta, California) and transported in Regan-Lowe medium or saline solution for microbiological processing. The samples were inoculated onto Regan-Lowe medium (Oxoid, Hampshire, United Kingdom) with 10% horse blood (Difco; BD Biosciences, San Jose, California) and 40 µg/mL cephalexin (Oxoid) and then incubated at 35-37°C for 10 days. If the cultures were compatible with B pertussis, they were confirmed by Gram staining and agglutination with rabbit antisera (Remel, Lenexa, Kansas). Simultaneously, bacterial DNA was extracted for molecular testing using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Detection of B pertussis was performed using RT-PCR, amplifying the IS481 and ptxS1 genomic targets and using the RNase P gene as an internal control. The bacterial DNA of the strain of B pertussis ATCC BAA-589 served as a positive control. All reactions were performed in triplicate using TaqMan Universal Master Mix II with UNG (Applied Biosystems, Foster City, California) on an Applied Biosystems 7500 Fast Real-Time PCR System platform. The primers, probes, and cycling conditions were followed as described previously. 13 In samples with IS481 (+) ≤35 cycles and ptxS1 (−), Bordetella holmesii was suspected and RT-PCR was performed using hIS1001 target. For the cases with IS481 (−) and ptxS1 (+), Bordetella parapertussis was suspected, requiring RT-PCR using the IS1001 target. 13 As positive controls, a strain of B holmesii ATCC 700053 and a strain of B parapertussis ATCC 15989 were used.
IS481 and ptxS1 positivity and respective cycle threshold (CT) were evaluated using a previously proposed algorithm. 13 The positive results for both targets, IS481 and ptxS1, were considered to confirm the presence of B pertussis. Results with IS481 (+) ≤35 cycles and ptxS1 (−) were considered Bordetella spp, whereas those with IS481 (+) ≥35 cycles and ptxS1 (−) were reported as indeterminate results.
When a patient tested positive for B pertussis based on PCR or culture, his or her household contacts and others with whom he or she had a close relationship (contact with the index case of at least 5 days a week in the 3 weeks before pertussis was diagnosed, regardless of the number of hours of exposure) were analyzed. All of the patient's contacts were invited to and interviewed at the hospital to assess their symptoms. Symptomatic contacts were defined as those who presented with productive or dry cough persisting for at least 1 week during the last 3 weeks before onset of the index case symptoms, regardless of the presence of fever and rhinorrhea. Contacts underwent a nasopharyngeal swab for culture and PCR testing using the same procedure used for the index cases. Culture and RT-PCR for B pertussis were performed, but the presence of B holmesii in household contacts was not investigated.
This study was approved by the Ethics and Research Committee of the INP, following the guidelines of the latest revision of the Declaration of Helsinki (October 2008). Written informed consent was obtained from a parent or guardian of each child enrolled in the study.
Statistical Analyses
All statistical analyses were performed using SPSS 22.0 for Windows (IBM, Armonk, New York). The numerical variables are summarized as median and range, except for the hematologic values, for which mean, SD, and 95% CI are used. The categorical variables are described as frequencies and percentages. Categorical and numerical variables were compared using the Mann-Whitney U or Kruskal-Wallis test, and categorical variables were compared using the Pearson c 2 or Fisher exact test.
Results
During the 3-year study, a total of 323 patients were included and 37 of them were excluded for not having complete clinical and epidemiologic information. Of the 286 patients included, 192 (67.1%) had B pertussis, 13 (4.5%) had Bordetella spp and 3 (1%) had suspected B parapertussis with samples IS481(−) and ptxS1(+), and 38 patients (13.3%) were classified as indeterminate. Finally, 40 patients (14%) had no amplification for any of the targets, and so were classified as negative (Figure) . The 192 patients with confirmed pertussis included 97 boys (50.5%) and had a median age of 60 days (range, 12 days to 10.5 months). The age distribution was as follows: <1 month, n = 14 (7.3%); 1-3 months, n = 145 (75.5%); 4-6 months, n = 25 (13%); 7-9 months, n = 7 (3.6%); 10-12 months, n = 1 (0.5%).
In the 192 patients with B pertussis, the predominant symptoms were cough (99%), including paroxysmal cough (89.6%), posttussive emesis (34.9%), and cyanosis (86.5%). Clinical data are presented in Table II . Of these symptoms, the prevalence of cyanosis was statistically significantly higher (P = .04) in the patients with B pertussis compared with those with negative results. Fever was present in 23% of the patients with pertussis and was significantly higher in patients with negative PCR results (P = .018). The median interval between the onset of symptoms and hospitalization was 10 days (range, 1-70 days).
The majority (71.5%) of the patients had a cough for <2 weeks, and 40.5% had a cough for <7 days. In the latter group, 75% of the patients were aged <3 months. Infants under 3 months had an average duration of cough of 11 days, and 36% had a cough for <1 week.
Thirty-eight patients (19.8%) with B pertussis had at least 1 complication. Twenty-six patients (13.5%) required mechanical ventilation, pneumonia was documented in 21 patients (11%), and 12 patients (6%) had a neurologic complication. The mean age of the patients who developed complications was 76.1 ± 68.6 days. Younger children required mechanical ventilation more frequently than older children (64.8 vs 84.5 days; P = .002). Patients with complications had significantly more severe leukocytosis (44 690 vs 22 220 cells/mm 3 ; P = .0002) and higher neutrophil counts (39 700 vs 27 100 cells/mm 3 ; P = .000001). We found that 34% of the patients who developed any complication died. Therefore, the presence of complications is a risk factor for death, with an OR of 11.28. In this series, 6.7% of the patients with B pertussis died, and only 1 patient had an underlying condition (aortic coarctation). The mean age of the patients with fatal pertussis was 55.5 ± 34.4 days. Patients with fatal pertussis were significantly younger (55.5 days vs 81.3 ± 55.1 days, P = .049), had more severe leukocytosis (63 343 vs 22 309 cells/mm 3 ; P = .001), and had a higher neutrophil count (47 800 vs 28 300 cells/mm 3 ; P = .00004). Fever was the sole statistically significant clinical manifestation associated with complications (P = .004) and mortality (P = .012).
Patients who tested negative for B pertussis also experienced complications, but no deaths were reported. The complications are listed in Table III .
Complete blood count results were obtained from 177 patients with B pertussis (92.2%). Of these patients, 59% had leukocytosis (>17 500 cells/mm 3 ), with a mean leukocyte count of 26 900 cells/mm 3 . The patients with leukocytosis had a mean age of 87.1 ± 56.6 days. Lymphocytosis (≥60%) was present in 64.4% of patients, with a mean lymphocyte count of 15 400 cells/mm 3 and a mean lymphocyte percentage of 62%. Atypical lymphocytes were detected in 14 patients (7.3%). Patients with lymphocytosis had a mean age of 88.9 ± 61.5 days. Only 40% of the patients had both leukocytosis and lymphocytosis. The mean age of the patients with both conditions was 95.7 ± 62.4, compared with 76.8 ± 54.2 days (P = .042). Leukocyte and lymphocyte counts were similar for patients with detected B pertussis and and those with Bordetella spp. The numbers of leukocytes and total lymphocytes were significantly higher when the result was B pertussis than when the result was indeterminate or negative (P < .001) ( Table IV) .
For the patients with B pertussis, the median CT values were 21.21 cycles (range, 7.9-36.94) for IS481 and 28.43 cycles (range, 15.44-41.33) for ptxS1. There was a linear correlation between the 2 targets of 7.22 cycles. Of the 13 patients who tested positive for Bordetella spp with IS481(+) ≤ 35 cycles and ptxS1(−), B holmesii was suspected; nevertheless, all cases were negative for the hIS1001 target. In these cases, the amplification of the DNA control was correct. We could not confirm the presence of B bronchiseptica because the cultures were negative, and it was not possible to perform specific PCR for this species. Based on the algorithm, these samples were classified as Bordetella spp.
Cultures were taken from 243 of the 286 patients (85%). In 153 patients (80%) with a positive PCR for B pertussis, a culture was performed, and was positive in only 22 patients (14%), with a average CT for IS481 of 23.01. No patient with a negative PCR test result for B pertussis had a positive culture.
According to the vaccination information obtained for all patients with B pertussis, 78 (40.6%) were not old enough for vaccination, 82 (42.7%) had an incomplete vaccination schedule, and only 32 (16.6%) were adequately vaccinated for their age. The relationship between vaccination status and the number of doses according to age is presented in Table V (available at www.jpeds.com). Analysis of the association between vaccination status and development of leukocytosis and/or lymphocytosis revealed that the only statistically significant association was the tendency to develop leukocytosis in unvaccinated patients (P = .051), whereas there was no association for lymphocytosis (P = .942). Analysis of the association between the number of vaccine doses administered and the development of complications and mortality found no statistically significant differences. The only significant difference was shown for the need for mechanical ventilation, in which 2 of the 64 patients (3.1%) who had received any dose of vaccine required ventilation, compared with 32 of 222 patients (14.4%) who had not been vaccinated (P = .014).
Of the 192 confirmed B pertussis cases, 119 had at least 1 contact (62%). A total of 434 contacts were analyzed; of these, 111 were mothers of the cases, 71 were fathers, 46 were siblings, 
Discussion
This multicenter study in Mexico has demonstrated the need for molecular diagnostics to detect B pertussis to enhance the diagnosis of pertussis and reduce underreporting and underdiagnosis worldwide. 4, 5 As in other countries, the use of molecular diagnostics in Mexico has had a major impact on the diagnosis of pertussis and the knowledge of the epidemiology of the disease. For example, the average annual number of confirmed cases was 218 from 2000 to 2011, but rose to 715 cases for 2012-2014, an increase of 227%, and then to 845 in 2015.
14 This significant improvement in the detection of B pertussis is related in part to the establishment of the Red Nacional de Laboratorios de Salud Pública para el Diagnóstico de Tos Ferina (National Network of Public Health Laboratories for the Diagnosis of Whooping Cough), an organization comprising 26 laboratories and a national reference laboratory, which implemented the use of RT-PCR for diagnosing pertussis. 9 In Mexico, 83% of reported pertussis cases occur in infants aged <1 year, 14 a similar percentage to that reported globally. 4, 5 In this study, we included only patients aged <1 year. The majority of pertussis cases occur in infants aged <6 months. In our series, 96% of pertussis cases occurred in infants aged <6 months, and 83% occurred in infants aged <3 months. This age group predominated because these children had not yet been vaccinated or completed their vaccination schedule, in concordance with previous reports. 5, 6, 15 In our cohort, cough and cyanosis were the main symptoms, similar to other reports. [16] [17] [18] The presence of cyanosis was statistically significant in the patients with B pertussis, in agreement with the results reported by Bellettini et al 19 (P < .0001). The rates of paroxysmal cough, posttussive emesis, and inspiratory "whoop" were similar to those reported by other authors. [16] [17] [18] [19] [20] [21] Cough persisting <14 days was documented in 71.4% of patients, and cough persisting <7 days was found in 40.5%. This finding is relevant because in the clinical evaluation of infants, cough persisting for >2 weeks should not be a criterion for a diagnosis of pertussis. Cherry et al noted that although the majority of international definitions use the presence of cough for >14 days as a criterion for epidemiologic purposes, in children aged <3 months, a specific duration of cough is unimportant. 22 Although fever generally is not considered a common sign in pertussis, it was present in 23% of out cohort, similar to other reports, and may indicate a secondary bacterial complication in some cases. 17, 21, 23 Pneumonia was the most frequent complication in our cohort, as it has been in most previously reported series, accounting for 15%-18% of all complications, 15, 21, 24 although some authors have reported frequencies of <10%. 23, 25 In our series, 13.5% of the patients required mechanical ventilation, similar to the 12.1%-17.3% reported by others. 23, 26 There was a clear association between younger age and the need for mechanical ventilation. In addition, there was an association between more severe leukocytosis (38 114 vs 19 619 cells/mm 3 ; P = .00003) and the development of complications, as has been reported previously. 23, 27 The World Health Organization reports an estimated mortality of pertussis of <1%. 4 This rate varies between developed and underdeveloped countries. In the US, the reported mortality rate of pertussis ranges from 0.5% to 1.3%, 15, 28 whereas in Latin American countries, the rate is higher, reaching 2.5% in Brazil, 19 4.9%-6.8% in Argentina, 18, 23, 26 and 5.8% in Peru. 29 Another study conducted in Mexico reported a mortality of 8.5%. 30 In our study, we also found a high mortality (6.7%), mainly because many patients arrived in advanced stages of the disease and with complications. It is well known that the majority of deaths occur in children aged <3 months. 5, 6 In our cohort, the infants who died were younger and had more severe leukocytosis. Gentile et al 23 also reported higher mortality in younger children and in children with a leukocyte count >30 000 cells/mm 3 (P = .001). Leukocytosis is reported in 24%-76% of pertussis cases. 18, 19, 29 In our cohort, 59% of the patients had leukocytosis. The presence of leukocytosis and lymphocytosis was statistically significant in patients with B pertussis detected compared with a negative PCR, which coincides with other reports. 16, 19 In our patients with a leukocyte count >100 000 cells/mm 3 (n = 5), death occurred in 80%, and most of these infants had fever. In relation to vaccination, 40.6% of our patients were too young for vaccination, and only 16.6% of the vaccine-eligible infants were correctly vaccinated for their age. Other studies also reported that between 30%-50% of the patients had not received any vaccine, whereas others had incomplete schedules. 15, 17, 23, 26, 31 Only 14% of our infants with B pertussis detected had a positive culture, which is in accordance with the rates of 12%-19% documented by other authors, 20, 23, 32 although some other reported positive culture rates <10%, 31 whereas others reported high rates, between 60% and 71%. 16, 17 This study was based on the multitarget RT-PCR strategy. 13 The performance of PCR based exclusively on IS481 is highly sensitive; however, it can give false-positive results, because B holmesii has 32-65 copies of IS481. In addition, it is not possible to detect B parapertussis using this target exclusively. 13, 33 In this study, B holmesii and B parapertussis were not routinely detected, and we cannot document the occurrence of co-infection with these pathogens, particularly with B holmesii, as previously reported. Nevertheless, the majority of cases of B holmesii are reported in adolescents. 34 A recent publication reported on the harmonization of the RT-PCR tests used to detect B pertussis in 50-53 different public health laboratories in the US. According to this report, 94%-96% of the laboratories use IS481 as the main genomic target, and 76%-86% use a multitarget strategy to detect B pertussis. 35 In numerous countries, PCR positivity is now included as part of the diagnostic criteria and case definitions. 5, 22 In Mexico, reporting pertussis is mandatory, a positive PCR result is now included as a criterion for confirming the disease, 5 and the network of public health laboratories has adopted a multitarget PCR strategy. 9 In our series, the source of B pertussis infection was confirmed in 48% of the cases, similar to previous reports. 12, 25, 36 We identified 434 contacts, of which mothers were the most common contact source evaluated and had the highest positivity for B pertussis (37%), a finding that conforms with other reports. 36 However, other studies have reported siblings as the main source of infection, in 41%-51% of cases.
11, 21 Skoff et al 24 recently reported an extensive series that demonstrated a clear shift in the source of B pertussis infection in the US, from mothers (20.6%) to siblings (35.5%). We found that contacts with B pertussis were more frequently symptomatic (75%), also in agreement with other reports, in which 54%-92% of cases were symptomatic contacts. 25, 37 In addition to the contacts who were positive for B pertussis, another 50% also had a positive PCR that was identified as Bordetella spp (11%), and 39% had an indeterminate PCR. These contacts also could have been colonized with B pertussis and been a potential source of transmission. Given the high CT for IS481 in these specimens, we could not obtain positivity for ptxS1; therefore, we presume that they had low density of B pertussis in the nasopharynx.
This prospective multicenter study of pertussis in Mexico implemented a multitarget RT-PCR strategy to diagnose pertussis and an extensive search with PCR testing of household contacts, establishing their important role in pertussis transmission. A limitation of this study is that we did not search for coinfection with B holmesii and B parapertussis or respiratory viruses, even though such coinfections have been reported in 15%-20% of pertussis cases. 16, 19 Our study confirms the usefulness of RT-PCR as a diagnostic tool for detecting B pertussis in developing countries. In our cohort, all reported cases occurred in unvaccinated or incompletely vaccinated infants. The complication and mortality rates of pertussis remain high. The role of household contacts, particularly mothers, as sources of B pertussis infection for infants is clear. The reemergence of pertussis in Mexico should encourage physicians and health authorities to strengthen vaccination policies and implement new strategies, such as vaccination of adolescents and adults, in an effort to reduce morbidity and mortality in children. ■ 
